COVID-19 and calprotectin's clinical value

21. Dec 2021 | 6 min read

COVID-19 and calprotectin's clinical value

Calprotectin as a valuable prognostic marker in care of COVID-19 patients

The rising numbers of SARS-CoV-2 infections during the recent weeks are again pushing the health systems to their limits. Early identification of infected patients who will develop severe COVID-19 can help hospitals to better allocate essential resources.

The role of calprotectin (plasma and serum) in early identification of neutrophil activation and hyper-inflammatory response in both COVID-19 and COVID-19 related sepsis has been confirmed in several studies. These research results indicate that calprotectin can be used in the risk assessment and prediction of which COVID-19 patients are at risk of developing severe complications such as respiratory failure and/or mortality.

Therefore, calprotectin can be used as a valuable biomarker for early evaluation of the disease severity and identification of patients at risk to progress to severe form of the disease, contributing to effective triage and care of COVID-19 patients.

Below you will find more information about plasma and serum calprotectin related to COVID-19. If you are interested in more information about calprotectin or in validation at your laboratory, please reach out to marketing@gentian.com


WEBINAR: The role of calprotectin in COVID-19

 

GCAL and COVID-19 9110v01

 

 

ARTICLES AND STUDIES

FAQ: Why is calprotectin upregulated in COVID-19?

FAQ: What role can plasma & serum calprotectin play in severe COVID-19?

Studies Demonstrate Use of Gentian Calprotectin Test to Triage COVID-19 Patients


Study confirms significantly elevated levels of calprotectin in patients with severe COVID-19

The role of Calprotectin in COVID-19 – results from clinical studies

New study results confirm the value of calprotectin in management of COVID-19 patients

Multicenter study confirms calprotectin’s role in risk stratification in COVID-19

 

New call-to-action


Contact us for further information

GCAL® is an immunoassay applied to turbidimetry-based clinical chemistry platforms. It is an open channel assay, meaning it can be added to all clinical chemistry analysers.

  • CE-marked since 2017
  • IVDR registration in progress
  • Developed and manufactured by Gentian
  • Manufactured according to ISO 13485:2016

Explore GCAL® in your laboratory - fill out the form or send an email to marketing@gentian.com for more information about the product and prices.

 

SARS-CoV-2 Total Antibody Immunoassay

You may also read


COVID-19 and calprotectin's clinical value

Dec 21, 2021

COVID-19 and calprotectin's clinical value

Calprotectin as a valuable prognostic marker in care of COVID-19 patients The rising numbers of SARS-CoV-2..

Webinar: SARS-CoV-2 Total Antibody Immunoassay - Launch soon

Dec 01, 2021

Webinar: SARS-CoV-2 Total Antibody Immunoassay - Launch soon

SARS-CoV-2 Total Antibody Immunoassay - Soon on chemical analysers In the effort to restrain the COVID-19..

Webinar: The biomarker calprotectin - for plasma and serum

Nov 30, 2021

Webinar: The biomarker calprotectin - for plasma and serum

Biomarker for early detection of the inflammatory response to infections Calprotectin is one of the earliest..